[{"address1": "80 Guest Street", "address2": "Suite 601", "city": "Boston", "state": "MA", "zip": "02135", "country": "United States", "phone": "(617) 500-8099", "website": "https://www.compasstherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 32, "companyOfficers": [{"maxAge": 1, "name": "Dr. Thomas J. Schuetz M.D., Ph.D.", "age": 62, "title": "Chief Executive Officer", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 835875, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vered  Bisker-Leib M.D., MBA, Ph.D.", "age": 52, "title": "Senior Consultant", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 719000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Neil L. Lerner CPA", "age": 56, "title": "Vice President of Finance", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jonathan  Anderman J.D.", "title": "VP, Head of Legal & Corporate Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Anna  Gifford", "title": "Communications Manager", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Minori  Rosales M.D., Ph.D.", "age": 60, "title": "Senior VP & Head of Clinical Development", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karin  Herrera B.A.", "title": "VP & Head of Clinical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James  Kranz Ph.D.", "title": "VP and Head of Chemistry Manufacturing & Controls", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1719792000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.82, "open": 0.82, "dayLow": 0.765, "dayHigh": 0.87, "regularMarketPreviousClose": 0.82, "regularMarketOpen": 0.82, "regularMarketDayLow": 0.765, "regularMarketDayHigh": 0.87, "beta": 0.624, "forwardPE": -1.7777779, "volume": 475017, "regularMarketVolume": 475017, "averageVolume": 353337, "averageVolume10days": 553180, "averageDailyVolume10Day": 553180, "bid": 0.7841, "ask": 0.827, "bidSize": 100, "askSize": 300, "marketCap": 110071192, "fiftyTwoWeekLow": 0.765, "fiftyTwoWeekHigh": 3.04, "fiftyDayAverage": 1.35352, "twoHundredDayAverage": 1.638005, "currency": "USD", "enterpriseValue": -44770664, "floatShares": 98066682, "sharesOutstanding": 137588992, "sharesShort": 1583727, "sharesShortPriorMonth": 1635650, "sharesShortPreviousMonthDate": 1715731200, "dateShortInterest": 1718323200, "sharesPercentSharesOut": 0.0115, "heldPercentInsiders": 0.12041, "heldPercentInstitutions": 0.70883006, "shortRatio": 5.77, "shortPercentOfFloat": 0.0163, "impliedSharesOutstanding": 137588992, "bookValue": 1.142, "priceToBook": 0.7005254, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -45444000, "trailingEps": -0.35, "forwardEps": -0.45, "enterpriseToEbitda": 0.849, "52WeekChange": -0.7306397, "SandP52WeekChange": 0.26253593, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CMPX", "underlyingSymbol": "CMPX", "shortName": "Compass Therapeutics, Inc.", "longName": "Compass Therapeutics, Inc.", "firstTradeDateEpochUtc": 1617629400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "2da7fead-7fe9-351a-a396-4dd759234d3a", "messageBoardId": "finmb_266166780", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.8, "targetHighPrice": 10.0, "targetLowPrice": 7.0, "targetMeanPrice": 8.83, "targetMedianPrice": 9.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 156255008, "totalCashPerShare": 1.136, "ebitda": -52763000, "totalDebt": 1413000, "quickRatio": 40.137, "currentRatio": 40.743, "debtToEquity": 0.9, "returnOnAssets": -0.19128, "returnOnEquity": -0.27349, "freeCashflow": -26013750, "operatingCashflow": -42277000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-08"}]